Wall Street analysts expect Agenus Inc (NASDAQ:AGEN) to post earnings per share of ($0.30) for the current quarter, according to Zacks. Three analysts have issued estimates for Agenus’ earnings, with the highest EPS estimate coming in at ($0.27) and the lowest estimate coming in at ($0.32). Agenus posted earnings of ($0.38) per share in the same quarter last year, which suggests a positive year over year growth rate of 21.1%. The firm is expected to announce its next earnings report on Thursday, August 13th.
According to Zacks, analysts expect that Agenus will report full-year earnings of ($1.14) per share for the current financial year, with EPS estimates ranging from ($1.24) to ($1.00). For the next financial year, analysts expect that the company will post earnings of ($1.13) per share, with EPS estimates ranging from ($1.29) to ($0.84). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Agenus.
Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.31) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.02. The firm had revenue of $15.13 million during the quarter, compared to analyst estimates of $12.35 million.
Shares of AGEN stock traded down $0.17 during trading hours on Tuesday, reaching $4.07. The stock had a trading volume of 10,732,157 shares, compared to its average volume of 2,583,602. Agenus has a twelve month low of $1.82 and a twelve month high of $4.78. The firm has a 50-day simple moving average of $2.66 and a 200-day simple moving average of $3.24. The firm has a market capitalization of $696.30 million, a PE ratio of -3.28 and a beta of 2.05.
Several institutional investors and hedge funds have recently made changes to their positions in AGEN. State Street Corp grew its stake in shares of Agenus by 14.8% in the 3rd quarter. State Street Corp now owns 2,399,958 shares of the biotechnology company’s stock worth $6,192,000 after purchasing an additional 309,954 shares during the last quarter. Advisor Partners LLC acquired a new position in shares of Agenus in the 4th quarter worth approximately $102,000. California Public Employees Retirement System grew its stake in shares of Agenus by 26.3% in the 4th quarter. California Public Employees Retirement System now owns 233,141 shares of the biotechnology company’s stock worth $949,000 after purchasing an additional 48,502 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Agenus in the 4th quarter worth approximately $60,000. Finally, Hussman Strategic Advisors Inc. acquired a new position in shares of Agenus in the 4th quarter worth approximately $610,000. 46.74% of the stock is currently owned by institutional investors.
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Further Reading: What are Institutional Investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.